Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for Disc Medicine in a report released on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($3.88) per share for the year, up from their prior forecast of ($3.91). HC Wainwright currently has a "Buy" rating and a $118.00 target price on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.15) per share. HC Wainwright also issued estimates for Disc Medicine's Q4 2024 earnings at ($0.88) EPS, Q1 2025 earnings at ($1.02) EPS, Q2 2025 earnings at ($1.17) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($1.50) EPS.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15.
IRON has been the topic of a number of other reports. Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target on the stock in a report on Tuesday, November 5th. Wells Fargo & Company initiated coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a "buy" rating and a $89.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and set a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Disc Medicine has a consensus rating of "Buy" and an average target price of $85.80.
Check Out Our Latest Research Report on IRON
Disc Medicine Stock Performance
NASDAQ IRON traded down $1.21 during mid-day trading on Friday, reaching $59.46. 270,748 shares of the stock were exchanged, compared to its average volume of 355,189. The business's 50 day moving average is $51.20 and its 200-day moving average is $44.97. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60. The company has a market capitalization of $1.77 billion, a P/E ratio of -14.94 and a beta of 0.60.
Insider Buying and Selling
In other Disc Medicine news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 7,538 shares of company stock worth $437,875. Insiders own 4.24% of the company's stock.
Hedge Funds Weigh In On Disc Medicine
A number of institutional investors have recently bought and sold shares of IRON. Amalgamated Bank raised its stake in Disc Medicine by 76.9% during the second quarter. Amalgamated Bank now owns 568 shares of the company's stock worth $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $129,000. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $131,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
See Also
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.